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7-Azido-8-[rz51]ketanserin ([rZSI]AZIK) was characterized as a potent photoaffinity probe for serotonin& 
receptors. In reversible binding experiments, [‘251]AZIK bound with high affinity (Kd = 0.69 nM) to rat fron- 
tal cortex membranes. When incubation with [‘251]AZIK was followed by UV irradiation, the binding was 
found to be irreversible. Protection experiments with various drugs demonstrated the serotonin-S2 nature 
of the photoaffinity labelling. SDS-polyacrylamide gel electrophoresis of the photolabelled membranes al- 
lowed one to identify the serotonin-S2 receptor ligand binding site as a single polypeptide with a molecular 
mass of approx. 67 500 Da. [‘251]AZIK will be a valuable tool for the elucidation of the serotonin-S2 receptor 
structure. 
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1. INTRODUCTION 
Several serotonin-binding sites have been iden- 
tified in various brain areas using in vitro 
radioligand binding assays. Amongst these, the 
serotonin-Sz receptor is pharmacologically the best 
characterized. The receptor shows high affinity for 
several serotonin antagonists and a low affinity for 
serotonin. Numerous functional correlates were 
established between the potency of antagonists to 
inhibit serotonin-mediated responses in phar- 
macological tests and their potency to inhibit 
radioligand binding to serotonin-S2 receptors [l]. 
Serotonin-S2 receptors were first identified in 
vitro in rat frontal cortex tissue with [3H]spiperone 
[2]. Later on, [3H]ketanserin was introduced as the 
first selective serotonin-Sz receptor ligand [3]. 
Recently, a derivative of ketanserin, 7-[3H] 
aminoketanserin, was characterized as a potent 
Correspondence address: W. Wouters, Laboratory of 
Endocrinology, Dept of Life Sciences, Janssen Phar- 
maceutica, B-2340 Beerse, Belgium 
radioligand with very low non-specific binding [4] 
and an iodinated analogue, 7-amino-8-[1251]ke- 
tanserin ([‘251]AMIK), was introduced as the first 
selective serotonin-S2 radioligand with high 
specific radioactivity [5]. 
The isolation, purification and molecular 
characterization of serotonin-S2 receptors have on- 
ly very recently been tackled. Solubilization of 
biologically active serotonin-Sz receptors was 
achieved using lysophosphatidylcholine as 
detergent [6]; however, solubilization yields were 
very low. Optimal solubilization was obtained 
using a mixture of CHAPS (3-[(3-cholamidopro- 
pyl)dimethylammonio]-l-propanesulfonate) and 
salt [4,7]. These solubilized receptors could also be 
reconstituted into phospholipid vesicles [8]. 
A further step towards the elucidation of the 
serotoninS2 receptor structure was made possible 
by the introduction of the potent photoaffinity 
probe 7-azidoketanserin [9]. This new compound 
was shown to irreversibly inhibit the binding to 
serotonin-S2 and histamine-HI receptors following 
UV (ultraviolet) irradiation. Differential pho- 
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toinactjvation of either receptor could be achieved 
using a combination of selective brain tissues and 
specific displacers flO]. 
In the present report we describe the binding 
characteristics of a radioiodinated derivative 
of 7-azidoketanserin (7-azido-8-[‘“‘Ijketanserin 
([L”SI]AZIK)) and its use in the identification of the 
serotanin& receptor ligand binding site by 
photoaffinity labelling and subsequent SDS- 
p~ly~c~ylamide g l electrophoresis. 
7-azido-8-[‘251]ketanserin (7-azido-3-[2-[4-(4- 
fluorobenzoyl) - 1 - piperidinyljethyl] *8 - [X2’I]iodo -
2,4-(lH,3H)quinazolinedione; -2175 Ci/mmol) 
was custom synthesized and HPLC-purified by 
Amersham (Amersham, England). Acrylamide, 
SDS and Coomassie blue R 250 we% supplied by 
LRB (Bromma, Sweden); serotonin, imidazole, 
tr~~~loro~~et~~ acid, periodic acid, sulf~sali~yl~~ 
acid, NJV’ ~~ally~ta~ardiam~de, ba~~tr~~in a d 
~~zamidjne by Janssen Chimica (Beerse, 
3~~~iurn)~ EDTA, bovine serum albumin (BSA) 
and soybean trypsin inhibitor by Sigma (St. Louis, 
USA) and bufotenine and phenylmethylsulfonyl 
fluoride by Serva (Heidelberg, FlXC;). Protein 
molecular mass standards were obtained from 
BiaRad (Richmond, USA). All drugs were kindiy 
provided by their companies of origin. 
Female W&tar rats were killed by d~ap~ta~~on 
and their brains were removed from the skull. Pre- 
frantat cortex was rapidly dissected and im- 
mediately homogenized at a dilution of 1: 10 (w/v) 
(original wet wt of tissue per volume) in 0.25 M 
sucrose. A total mitochondrial plus microsomal 
(M + L + P)-fraction was prepared by differential 
cemrifugation as described [3]. The final pellet was 
suspended in 50 mM Tris-HCl, pH ?.7* at the in- 
dicated dilutions. When experiments were per- 
formed in the presence of protease inhibitors, the 
buffers contained 5 mM EDT s 0.05 mM hen- 
zamidine, 0.1 mM phenylm~th~ls~if~nyl fluoride, 
0.2 mg/mf bacitracin and 0.01 m&ml soybean 
trypsin inhibitor. 
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Aliquots (SO0 pi) of an M + L + P-fraction (diiu- 
tion 1: 500, w/v) were incubated in the dark at 
37°C for 115 min with l*251]AZIK and unlabtlled 
drugs ar their solvent in a total volume af 550 yl. 
Incubation was stopped by addition of 3 ml ice- 
cold Tris-HCl, pH 7.7, containing 120 mM sodium 
chloride and FolIowed by rapid filtration over 
Whatman GF/C glass fibre filters using a 
Multividar 4O-well filtration manifold (Janssen 
Scientific I~str~~~ents Division, Beerse, Bdgium)_ 
Filters were rinsed twice with 5 ml ice-cold buffer 
and were then colaated in an LKB 1271 gamma 
counter. 
2.4. Photolabelling 
1 ml aliquots of an M + L + P-fraction (dilution 
1: 100, w/v) were incubated in the dark at Jl’C! for 
15 min with [1251]AZIK and unlabelled drugs or 
their solvent. The samples were then cooled to 4°C 
and centrifuged at 39100 x g (rmax) for 10 min. 
The pellets were rehomogenized using a glass- 
teflon h~rn~~e~~zer in 50 mM Tris-NC& pH 7.7, 
~ont~~i~~ IQ mg/ml BSA at a final dilution of 
1: 300 (wbv), This suspension was irradiated at 4°C 
for 3 mia with long-wavelength UV-light (366 nm) 
in quartz test tubes at an average distance af 4 cm 
from a Camag ‘Universal UV-lamp (Camag, Mut- 
tenz, Switzerland). During irradiation the samples 
were continuously mixed using a multiaxle rotating 
mixer. Fallowing irradiation the samples were 
filtered through Whatman GF/C glass fibre filters, 
To remove unbound and reversibly bound 
radioiigand, filters were incubated at 37°C for 
5 min with 10 ml of 50 mM Tris-HCl, pH 7.7, 
~ont~n~~8 120 mM sodium chloride. This pro- 
cedure was repeated four times in total after which 
the filters were counted as described above, 
2.5. SDS-palyacrylumide gel electrophoresis 
1 ml aliquots of an M + L + P-fraction (dilution 
I : 100, w/v) were photoIabelled as described 
above. Following UV irradiation, the suspensions 
were diluted up to 1: IOOO (w/v) with 50 mM Tris- 
HCl, pH 7.7, and incubated at 37°C fur 14 min 
with f FM pipamperone to remove reversibly 
bound radioI~~and and then cooled to 4°C. The 
suspensions were centrifuged at 39100 x g (rmBx) 
for 10 min; the pellets were washed with the sac 
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volume of Tris-buffer and again centrifuged. The 
washed pellets were then transferred to Eppendorf 
microtubes with 1 ml of Tris-buffer and centri- 
fuged at 13000 rpm for 10 min. The pellets were 
solubilized in 50 pl SDS sample buffer (10 mM 
imidazole-phosphate, pH 7, 2010 (w/v) SDS and 
5% (v/v) 2-mercaptoethanol) and denatured by 
boiling for 3 min. 
10 ,uI aliquots were loaded on 2 mm thick 7.5% 
acrylamide slab gels (7.5% (w/v) acrylamide, 
0.3010 (w/v) N,N’-diallyltartardiamide, 0.1% 
(w/v) SDS and 50 mM imidazole-phosphate, pH 
7) together with protein molecular mass markers. 
Electrophoresis with a continuous buffer system 
was performed at 4°C for 105 min with a constant 
current of 100 mA using an LKB 2117 Multiphor 
and an LKB 2197 power supply. At the end of the 
run, the gel was fixed in a solution of 11.4% (w/v) 
trichloroacetic acid, 3.4% (w/v) sulfosalicylic acid 
and 30% (v/v) methanol for 1 h at room 
temperature. The protein markers were stained 
with 0.25% (w/v) Coomassie blue R 250 in 
methanol/water/acetic acid (46 : 46 : 8, v/v) for 2 h 
and destained in ethanol/water/acetic acid 
(30: 60: 10, v/v). The parts of the gel, containing 
the labelled samples were soaked in a preserving 
solution (ethanol/water/aceti~ acid/glycerol, 
30 : 50 : 10 : IO, v/v) for 1 h, dried and exposed at 
-70°C to Kodak X-omatic film using Kodak X- 
omatic regular intensifying screens. In some ex- 
periments the gels were cut into 2 mm slices and 
counted for radioactivity. 
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3. RESULTS 
3:l. Reversible bidding of f”I;IAZX 
Fig.1 shows a typical saturation curve for rever- 
sible [1251]AZIK binding to an M+L+ P-fraction 
from rat frontal cortex. The binding was saturable 
in the nanomolar range. Non-specific binding was 
about 50% of total binding at routine concentra- 
tions (0.3 nM) increasing to more than 60% at full 
saturation. Scatchard analysis of the specific 
binding data showed a straight line; from four in- 
dependent experiments, an equilibrium dissocia- 
tion constant (&) of 0.69 * 0.21 nM and a 
maximal number of binding sites (Bmax) of 21.0 f 
3.5 fmollmg tissue could be derived. Several com- 
pounds were tested for their potency to inhibit 
reversible [‘2SI]AZIK binding. For all the com- 
pounds, monophasic inhibition curves were ob- 
tained. The derived IGO values are summarized in 
table 1. Serotonin antagonists (ketanserin, 
pipamperone and methysergide) inhibited 
[‘251]AZIK binding at nanomolar concentrations; 
serotonin agonists (serotonin and bufotenine) were 
active at micromolar concentrations. Compounds 
with other pharmacological profiles (prazosin, 
al-adrenergic antagonist; pyrilamine, histamine- 
Hi antagonist; and domperidone, dopamine-D2 
antagonist) were poorly or not active. 
3.2. Photoiabelling with [“‘I]AZIK 
As shown in fig.2, the amount of specific 
photolabelling increased with the [*2SI]AZIK con- 
B 
[‘2S,] AZIK CONCENTRATlONlnMl B 1 pm01 /ml 1 
Fig.1, (A) Typical saturation curves of reversible total (O---O) and specific (O--O) [‘2511AZIK binding to an 
M + L + P-fraction of rat frontal cortex. (B) Scatchard analysis of specific binding. Binding was performed as described 
in section 2. Specific binding was calculated as the difference between total binding and binding in the presence of a 
thousandfold excess of pipamperone. 
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Table 1 
~ompetitjon f various ~orn~ou~~ in reversible 
I’25fjAXIK binding and potencies of these compounds 
for protection against photoiabeiling with [‘251]AZIK in 
a membrane preparation of rat frontal cortex 
- 
Compound - log ICJO (Ml 
Fig.2, P~otoIab~I~~~g of rat froRtaI cortex rn~rn~~~~~~ as 
a &m&m af ~‘*~~~AZ~K o~~~tra~io~ (if---o, total 
pho~#IabeI~~~g~ A---& * non-specific phot~~~be~Iing~ 
+-+, specific phot~~a~~~~~g~. hotoIabeI1~~~ was 
performed as described in section 2 using a tho~sa~df~id 
excess of pipamperone to define specific photolabelling. 
centration, reaching a maximum at 1.2 nM 
radioligand concentration. To obtain the optimal 
ratio between specific and tota p~otoiab~i1~~~ it 
was necessary to remove the excess of free azide 
0 I 2 3 & 5 6 7 8 9 10 
CPM PER SLICE lxlt+) 
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after the incubation, prior to UV irradiation. A 
further increase could be obtained from the inclu- 
sion of BSA as a free radical scavenger during 
photolysis. Using these optimal conditions in 
routine experiments (0.3 nM [12SI]AZIK), specific 
photolabelling reached about 70% of total 
photolabelling. 
Several compounds were tested for their potency 
to protect the receptor against photolabelling with 
[1251]AZIK. They were included at increasing con- 
centrations during the incubation preceding the 
centrifugation step. The derived ICSO values are 
shown in table 1 and corresponded to those ob- 
tained for the reversible binding of [‘251]AZIK. 
3.3. SDS electrophoresis 
Aliquots of an M + L + P-fraction of rat frontal 
cortex (including protease inhibitors) were 
photolabelled using 0.5 nM [iz51]AZIK and subse- 
quently subjected to electrophoresis on a 7.5% 
SDS-polyacrylamide gel. Following electrophore- 
sis, part of the gel was used for autoradiography 
and the other part was sliced and counted for 
radioacti~ty, The results of a typical experiment 
are shown in fig.3. Specific serotonin-S2 receptor 
photolabelling was concentrated in one major 
band corresponding to a molecular mass of 67 595 
f 1324 Da (mean & SD, 7 independent determina- 
tions). Non-specific photolabelling was recovered 
in a broad band in the lower molecular mass region 
of the gel and in three faint bands with molecular 
masses of approx. 95, 52 and 34 kDa. Essentially 
the same results were obtained when protease in- 
hibitors were omitted from the incubation mix- 
tures or when 10% instead of 7.5% gels were used 
(not shown). Fig.3B shows the results of an experi- 
ment in which several compounds were included in 
the incubation, before photolysis. Radioactivity in 
the 67500 Da band could only be displaced by 
serotoninS2 antagonists (methysergide and 
pip~perone) and serotonin agonists (serotonin 
and bufotenine); the other compounds were poorly 
or not active. 
4, DISCUSSION 
Since [‘251]AMIK (an iodinated derivative of 
7-~inoketanserin) was found to be a potent, 
high-affinity ligand for the serotonin-S2 receptor 
[5], it was speculated that an iodinated analogue of 
7-azidoketanserin (a compound, previously shown 
to irreversibly block the serotoninS2 receptor after 
UV photolysis [9]) might be useful in photoaffinity 
labelling experiments. In the present report, 
[1251]AZIK was characterized as a high affinity 
ligand (& = 0.69 nM), capable of binding irrever- 
sibly to serotoninS2 receptors following UV ir- 
radiation. 
The extent of specific photoaffinity labelling 
was dependent on azide concentration. At satura- 
tion, about 25% of the reversible specific binding 
sites were photoIabelled. This compares 
favourably to the yields obtained with photoaffini- 
ty systems for other neurotransmitter eceptors 
(e.g. [I 1,121). Part of the specific binding may 
have been lost by dissociation of the ligand during 
centrifugation, prior to UV irradiation. This ex- 
perimental step was however necessary in order to 
keep non-specific photolabelling at a minimum+ 
Analysis of the photolabelled membranes by 
SDS electrophoresis howed specific incorporation 
of [1251]AZIK into one band with a molecular mass 
of 67500 Da. Displacement of radioactivity from 
this band revealed a clear serotonin-S2 profile. 
Since no additional specifically labelled bands were 
found (either in the presence or absence of pro- 
tease inhibitors) it may be concluded that this band 
corresponds to the serotonin-S2 receptor ligand 
binding site. Whether or not this binding site is 
part of a larger protein complex remains to be 
elucidated. Previous molecular mass estimates by 
gradient sedimentation of solubilized serotonin-S2 
receptors gave a value of approx. 80 kDa [7]. Un- 
fortunately in these experiments the contribution 
of the bound detergent could not be determined. 
Anyhow since solubilization was performed using 
a non-denaturing detergent (CHAPS/salt), and the 
value obtained in the present report was close to 
the one, it might tentatively be concluded that the 
serotoninS2 receptor consists of only one polypep- 
tide. Recently, a study using radiation inactivation 
revealed a molecular mass of around 60 kDa for 
the serotonin-Sz receptor ligand binding site [ 131. 
Based on the monoexponential decay curves they 
found in their experiments, these authors too con- 
cluded that the serotonin-S2 binding site probably 
does not involve a high molecular mass complex. 
In summary, we demonstrated that [‘251]AZIK is 
a very potent photoaffinity probe for the 
serotonin-S2 receptor. Since photoaffinity labelling 
363 
Volume 213, number 2 FEBS LETTERS March 1987 
can overcome a lot of detection problems during 
purification and characterization of a receptor 
protein, [‘2SI]AZIK will be a valuable tool in the 
search for the molecular structure of the serotonin- 
SZ receptor. 
ACKNOWLEDGEMENTS 
We thank Annie Nuyts and Yvette Dillen for 
secretaria work. Part of this work was supported 






Leysen, J.E., De Chaffoy de Courcelles, D., De 
Clerck, F., Niemegeers, C.J.E. and Van Nueten, 
J.M. (1984) Neuropharmacology 23, 1493-1501. 
Leysen, J.E., Niemegeers, C.J.E., Tollenaere, J.P. 
and Laduron, P.M. (1978) Nature 272, 168-171. 
Leysen, J.E., Niemegeers, C.J.E., Van Nueten, 
J.M. and Laduron, P.M. (1982) Mol. Pharmacol. 
21, 301-314. 
Wouters, W., Janssen, C.G.M., Van Dun, J., 
Thyssen, J.B.A. and Laduron, P.M. (1986j J. 










Wouters, W., Van Dun, J. and Laduron, P.M. 
(1986) Biochem. Pharmacof. 35, 3199-3202. 
Ilien, B., Gorissen, H. and Laduron, P.M. (1982) 
Mol. Pharmacol. 22, 243-249. 
Wouters, W., Van Dun, J., Leysen, J.E. and 
Laduron, P.M. (1985) Eur. J. Pharmacol. 115, 
l-9. 
Wouters, W., Van Hertrooy, J.J.C.C., Krekels, 
M.D.W.G. and Laduron, P.M. (1986) J. Rec. Res., 
in press. 
Wouters, W., Van Dun, J., Leysen, J.E. and 
Laduron, P.M. (1985) J. Biol. Chem. 260, 
8423-8429. 
Wouters, W., Van Dun, J., Leysen, J.E. and 
Laduron, P.M. (1985) FEBS Lett. 182, 291-296. 
Leeb-Lundberg, L.M.F., Dickinson, K.E. J., 
Heald, S.L., Wikberg, J.E.S., Hagen, P.-O., De 
Bernardis, J.F., Winn, M., Arendsen, D.L., 
Lefkowitz, R.J. and Caron, M.G. (1984) J. Biol. 
Chem. 259, 2579-2587. 
Lavin, T.N., Nambi, P., Heald, S.L., Jeffs, P.W., 
Lefkowitz, R.J. and Caron, M.G. (1982) J. Biol. 
Chem. 257, 12332-12340. 
Gozfan, Ii., Emerit, M.B., Hall, M.D., Nielsen, 
M. and Hamon, M. (1986) Biochem. Pharmacol. 
35, 1891-1897. 
364 
